Estudio del uso de cefepima en un hospital general

• Autores: Maite Sampere, Esperança Anton, Anisi Morón Besolí, Dionisia Fontanals Aymerich, G. Serrate
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 7, Nº. 2, 2005, págs. 97-104
• Idioma: español
• Títulos paralelos:
  • Cefepime's use in a general hospital
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction: Cefepime is a fourth-generation aminotriazole a-methoxamine cephalosporin with a wide spectrum of activity that includes both gram-positive and gram-negative aerobic bacteria. Material and methods: The study was developed at the Corporació Parc Tauli from 1998 to 2001. The patients treated with cefepime were identified through the database from the Pharmacy Department. For the study of sensitivity evolution, the computer database from the Microbiology Laboratory was used. During 18 months, a treatment protocol with cefepime was applied to patients with a suspicion of nosocomial respiratory infection. Results: Since 1998 to 2001, 45, 63, 86 and 166 patients have received cefepime, respectively. The total number of defined daily doses was 3362.7 and the average days of treatment were 7.9. The sensitivity of E. coli versus cefepime was of 99.5%. The sensitivity of P. aeruginosa versus the main antipseudomonal drugs being tested in our hospital was of 92.3% for piperacillin-tazobactam, amikacin 90.7%, piperacillin 89%, imipenem 87.3%, cefepime 84.6%, ceftazidime 81.9% and aztreonam 73.8%. S. aureus was sensitive in 80% of isolations versus cefepime and oxacillin. S. pneumoniae showed a percentage of sensitive strains that decreased from an initial 100% to 70% in the year 2001, while the sensitivity rates of S. pneumoniae during the same years versus cefotaxime were 90.5% and 89.8%. A prospective follow-up of 28 patients treated with cefepinie for suspicion of nosocomial respiratory infection took place; in 17 cases the diagnosis was nosocomial pneumonia. The evolution was favorable in 75.5% of cases, in one case the treatment was changed due to therapeutic failure and other three patients died